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Abstract
Background: Gomisin G, isolated from herb Schisandra chinensis, exhibits anti-tumor activities. Therefore, Gomisin G is 
a drug candidate for anti-liver cancer therapy.
Aims: To predict the metabolic behavior and metabolism-based drug-drug interaction of  gomisin G.
Methods: Molecular docking method was used. The crystal structure of  CYP3A4 with the ligand ketoconazole was chosen 
from protein data bank (http://www.rcsb.org/pdb). Chemdraw software was used to draw the two-dimensional structure of  
gomisin G with standard bond lengths and angles. 
Results: Gomisin G can be well docked into the activity site of  CYP3A4, and distance between gomisin G the heme active 
site was 2.75 Å. To evaluate whether the inhibitors of  CYP3A4 can affect the metabolism of  gomisin G, co-docking of  
gomisin G and ketoconazole was further performed. The distance between ketoconazole and activity center (2.10 Å) is clos-
er than the distance between gomisin G and activity center of  CYP3A4, indicating the easy influence of  CYP3A4’s strong 
inhibitor towards the metabolism of  gomisin G.
Conclusion: Gomisin G is a good substrate of  CYP3A4, and CYP3A4 inhibitors easily affect the metabolism of  Gomisin 
G.
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The liver plays an important role in filtering blood that 
circulates through the body. It can perform catalytic 
biotransformation process of  nutrients and drugs into 
the ready-to-use chemicals. It  can be affected by pri-
mary liver cancer, and by cancer which forms in other 
parts of  the body and then spreads to the liver1. Search-
ing efficient therapeutic drugs for liver cancers is very 
important and necessary.
Schisandra chinensis, also named wuweizi in Chinese, 
has wide application in clinic, including anti-tumor ef-
fects. Many efficient anti-tumor components have been 
isolated from Schisandra chinensis. For example, the 
lignans isolated from Schisandra chinensis showed an-
ti-proliferative activity in human colorectal carcinoma2. 
Schisandra chinensis polysaccharide exerts antitumor 
and antiangiogenic activity towards renal cell carcino-
ma model3. Schizandrin has been reported to exhibit 
anti-tumor activity4. Lignan component gomisin G is 
an important ingredient isolated from Schisandra chin-
ensis, and is a potent drug candidate for treatment of  
liver cancer.
Lignan components have been reported to be good 
substrates of  drug-metabolizing enzymes (DMEs). For 
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example, drug-metabolizing enzyme cytochrome P450 
3A catalyzes the biotransformation of  major lignan 
component schizandrin4. Therefore, the potential drug-
drug interaction between gomisin G and the inhibitor 
of  CYP3A ketoconazole was predicted using molecular 
docking in the present study. 
Materials and methods
The source of  the crystal structure of  CYP3A4 and 
molecular structure of  gomisin G
Preparation of  suitable crystal structure of  protein and 
chemical structure of  compound is the first key step 
for molecular docking. In the present study, the crys-
tal structure of  CYP3A4 with the ligand ketoconazole 
was chosen from protein data bank (http://www.rcsb.
org/pdb). The structure was processed using the pro-
tein preparation wizard in the Schrödinger suite of  pro-
grams, and the missing residues in the middle of  the 
chain were added, and hydrogen atoms were assigned. 
Chemdraw software was used to draw the two-dimen-
sional structure of  gomisin G with standard bond 
lengths and angles. 
Docking process
The gomisin G ligand docking and CYP450 3A4 pro-
tein-ligand complex studies were performed with Tri-
pos molecular modeling packages according to previ-
ous literature5,6. Firstly, the three-dimensional structure 
of  the gomisin G molecules was built and optimized by 
using the Tripos force field. The receptor-ligand bind-
ing geometry was optimized by using a flexible docking 
method with the Tripos FlexiDock program.
In this docking simulation, a CYP3A4 binding pock-
et was first defined to cover all residues within 4Å of  
the ligand in the initial CYP3A4-ketoconazole complex. 
During flexible docking by the FlexiDock module, all 
of  the single bonds of  residue side chains inside the 
defined 3A4 receptor binding pocket were regarded as 
rotatable or flexible bonds, and the ligand was allowed 
to rotate on all single bonds and move flexibly within 
the tentative binding pocket. The atomic charges were 
recalculated by using the Gasteiger–Huckel approach 
for the ligand. H-bonding site was marked for suitable 
atoms. The binding interaction energy was calculated to 
include van der Waals, electrostatic, and torsional ener-
gy terms defined in the Tripos force field. The structure 
optimization was performed for 20000-generations, 
using a Genetic Algorithm, and the 20 best-scoring li-
gand-protein complexes were kept for further analysis. 
The Flexidock simulation indicated that the obtained 20 
best scoring gomisin G-3A4 complex models have very 
similar 3D structures with little different
energies.
Results
The inhibitor ketoconazole was first extracted from 
the activity cavity of  CYP3A4, and then the structure 
of  gomisin G was docked into the activity cavity of  
CYP3A4. 
As shown in Figure 1, gomisin G can be well docked 
into the activity site of  CYP3A4, and distance between 
gomisin G the heme active site was 2.75 Å. To evaluate 
whether the inhibitors of  CYP3A4 can affect the me-
tabolism of  gomisin G, co-docking of  gomisin G and 
ketoconazole was further performed. 
Fig. 1 Molecular docking of  gomisin G into the activity cavity of  CYP3A4. The crystal structure of  CYP3A4 
with ketoconazole in the activity cavity (PDB code 2V0M) was selected from protein data bank (http://www.rcsb.
org/pdb). The structure of  ketoconazole was firstly extracted from the cavity of  CYP3A4 before the docking of  
gomisin G into the activity cavity.
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The distance between ketoconazole and activity center 
(2.10 Å) is closer than the distance between gomisin 
G and activity center of  CYP3A4 (Figure 2), indicat-
ing the easy influence of  CYP3A4’s strong inhibitor to-
wards the metabolism of  gomisin G.
Fig. 2 Co-docking of  both gomisin G and ketoconazole into the activity cavity of  CYP3A4. The green color rep-
resents the structure of  ketoconazole, and the purple color represents the structure of  gomisin G.
Discussion
The investigation of  metabolic behavior and metab-
olism-based drug-drug interaction plays an important 
role in the R&D of  new chemical entities towards new 
drugs. The development of  many new chemical entities 
with poor metabolic properties was limited. For exam-
ple, the anti-tumor drug candidate noscapine has been 
demonstrated to exhibit inhibition towards drug-me-
tabolizing enzyme cytochrome P450 (CYP) 3A4 and 
2C9, which strongly limited the R&D of  noscapine7. 
Additionally, CYP3A4 and CYP2C9-catalyzed metabol-
ic activation of  noscapine also increase the risk of  nos-
capine, limiting the development of  noscapine8,9. 
Molecular docking, predicting the preferred orientation 
of  one molecule into the second one, is frequently used 
to predict the binding orientation of  small drug can-
didates to their protein targets. Therefore, this meth-
od is suitable for the predicting the metabolic behavior 
through docking the compounds into the activity cavity 
of  drug-metabolizing enzymes. For example, Kobayas-
hi et al. used molecular docking method to determine 
the influence of  single nucleotide polymorphisms in 
CYP2B6 on substrate recognition10. Liu et al. used mo-
lecular docking to deeply understand the metabolic be-
havior of  GNF-351 by CYP3A4 and its potential drug-
drug interaction with ketoconazole11.
The present study aims to predict the interaction be-
tween gomisin G and CYP3A4, and the well docking of  
gomisin G into the activity cavity of  CYP3A4 indicated 
the good substrate of  gomisin G for CYP3A4. Addi-
tionally, the inhibitors of  CYP3A4 easily induce drug-
drug interaction with Gomisin G through inhibiting the 
metabolism of  gomisin G.
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